New FDA external relations head
This article was originally published in The Tan Sheet
Executive SummarySheila Dearybury Walcoff is named FDA associate commissioner for exteral relations, the agency announces Sept 7. Walcoff will advise Acting Commissioner Lester Crawford, PhD, on executive-level policy and program direction for FDA's interactions and liason activities. Walcoff most recently served as a senior associate at the law firm Mayer, Brown, Rowe & Maw (Washington, D.C.). She replaces Peter Pitts, who left the position in June to pursue an opportunity in the private sector (1"The Tan Sheet" June 7, 2004, p. 8)...
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.